Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

21
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
21
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

22
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
22
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

25
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
25
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

32
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
32

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional propriospinal myoclonus in Alzheimer's disease: coincidence or a new challenge?

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2025
Same author

Increased production of inflammatory cytokines by circulating monocytes in mesial temporal lobe epilepsy: A possible role in drug resistance.

Journal of neuroimmunology·2023
Same author

Dem-Aging: autophagy-related pathologies and the "two faces of dementia".

Neurogenetics·2023
Same author

Qualitative evaluation of the Rey-Osterrieth Complex Figure Test in patients with progressive supranuclear palsy.

The Clinical neuropsychologist·2022
Same author

Special Issue on new therapeutic approaches to Parkinson disease.

Neuropharmacology·2022
Same author

Adult-onset mitochondrial movement disorders: a national picture from the Italian Network.

Journal of neurology·2021
Same journal

Blood Pressure Control With Clevidipine Is Associated With Hematoma Volume Reduction in Acute Hypertensive Intracerebral Hemorrhage: A Single-Center Prospective Cohort Study.

European journal of neurology·2026
Same journal

CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence?

European journal of neurology·2026
Same journal

Direct Thrombectomy vs. Combined Treatment With Intravenous Thrombolysis in the Extended Time Window: A Target Trial Emulation.

European journal of neurology·2026
Same journal

Pharmacological Treatment of Cerebellar Ataxia in Pediatric Ataxia-Telangiectasia: A Systematic Review.

European journal of neurology·2026
Same journal

Intensive Rehabilitation With Adjunctive Bilateral Anodal tDCS in Post-Stroke Dysphagia: A Multicenter Randomized Controlled Trial.

European journal of neurology·2026
Same journal

Distal Agrin (AGRN) Congenital Myasthenic Syndrome With Mitochondrial Dysfunction.

European journal of neurology·2026
See all related articles

Related Experiment Video

Updated: Apr 27, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.5K

Doctor--how quickly will my Parkinson's progress?

S H Fox1, R Ceravolo

  • 1Movement Disorder Clinic, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada. sfox@uhnresearch.ca.

European Journal of Neurology
|July 5, 2014
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.9K

Related Experiment Videos

Last Updated: Apr 27, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

7.5K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.9K